Drug intelligence / Profile preview

PF-07905428

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Topical

Overview

PF-07905428 is an investigational small molecule drug developed by Pfizer for the treatment of acne vulgaris. It is administered topically as a solution and is currently in Phase 1 clinical trials. The specific mechanism of action has not been disclosed or characterized, and it does not represent a novel mechanism according to available sources. No brand names or alternative names have been reported, and there are no known FDA designations or approvals for this compound.

Beyond the preview

Go deeper on PF-07905428.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07905428.

Explore the full profile